Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores

BACKGROUND: The body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index predicts 5-year mortality risk in chronic obstructive pulmonary disease (COPD); higher scores predict worse outcomes. Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4/13, reduced exacerbations and improved lung function in patients with COPD in phase 3 BOREAS trial (NCT03930732). We assessed dupilumab efficacy in patients with COPD and type 2 inflammation by baseline BODE index. METHODS: Patients with COPD, moderate-to-severe airflow limitation, screening blood eosinophils

• Vogelmeier, C. F.
• Rabe, K. F.
• Bhatt, S. P.
• Hanania, N. A.
• Bafadhel, M.
• Christenson, S. A.
• Papi, A.
• Singh, D.
• Laws, E.
• Maloney, J.
• Dakin, P.
• Lu, X.
• Bauer, D.
• Bansal, A.
• Robinson, L. B.
• Abdulai, R. M.